ClinicalTrials.gg

Skin Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 606 studies for Skin Neoplasms across more than 10 countries. 127 are recruiting or about to start. 254 of them are mainly about Skin Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 7 narrower conditions too, such as Melanoma: 4,012 studies, 712 open.

ClinicalTrials.gov finds 19,561 studies for Skin Neoplasms. How that becomes 605 here

This page counts the studies the registry files under Skin Neoplasms, and those it files under no condition that list Skin Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 19,561Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −3,058Filed under a narrower condition, counted on its own pageMelanoma 2,991 · Blastic Plasmacytoid Dendritic Cell Neoplasm 45 · Basal Cell Nevus Syndrome 10 · Dysplastic Nevus Syndrome 5 · Uveal Melanoma 5
  3. −49List Skin Neoplasms as a condition, but the registry did not file them under itMost often written as “Non-melanoma Skin Cancer” (14), “Non-melanomatous Skin Cancer” (13), and “Skin Cancer Face” (6). The registry filed them under other conditions only, most often Carcinoma, Basal Cell (22) and Keratosis, Actinic (8).
  4. −15,849Match it another way52 name it in the title, 12 in a keyword, and 15,785 by a synonym or other text the search reads.
  5. 605The count on this page41 of them list Skin Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
294
Recruiting
105
Terminated
67
Active, not recruiting
50
Status unknown
40
Withdrawn
25

Phase

Phase 2
144
Phase 1
89
Phase 3
33
Phase 4
17
Early Phase 1
17

Where

United States
381
United Kingdom
40
France
40
Australia
36
Germany
31
Canada
28

Who develops what

Add Skin Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 8 companies, 1 with this as their studies’ main aim; 4 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Pfizer and Regeneron Pharmaceuticals here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
IpilimumabRecent, repeated
Evidence
  • NCT07815574 · Scancell Ltd · Phase 3 · live · background · “Nivolumab & Ipilimumab” · registered Sep 2026
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
  • NCT05926960 · Pfizer · Phase 2 · comparator · “ipilimumab” · registered Apr 2023
  • NCT01604889 · Incyte Corporation · Phase 2 · background · “ipilimumab” · registered May 2012
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)33 studies
NivolumabRecent, repeated
Evidence
  • NCT07815574 · Scancell Ltd · Phase 3 · live · background · “Nivolumab & Ipilimumab” · registered Sep 2026
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
  • NCT05926960 · Pfizer · Phase 2 · comparator · “nivolumab” · registered Apr 2023
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)33 studies
pembrolizumabRecent, repeated
Evidence
  • NCT06947928 · TuHURA Biosciences, Inc. · Phase 3 · live · background · “Pembrolizumab” · registered Apr 2025
  • NCT05608291 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Pembrolizumab” · registered Oct 2022
  • NCT03684785 · Exicure, Inc. · Phase 2 · background · “Pembrolizumab” · registered Sep 2018
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)22 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
cemiplimabApproved: US 2018 · EU 2019☆ Track1 live phase-3 study: NCT06585410Regeneron Pharmaceuticals

The 1 in phase 3 with the nearest primary completion, of 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Mar 2027 est.pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0 · TuHURA Biosciences, Inc. · Phase 3 registry mapping onlyadded to pembrolizumabNCT06947928 Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma — primary endpoint: Objective response rate (ORR) · 118 enrolled
  • 26 Oct 2027 est.A novel hGIIA-Vimentin Inhibitor · Filamon LTD · Phase 2 named, not the main aimNCT06926075 Early Phase Study of KESONOTIDE™in Participants With Solid Tumours — primary endpoint: To evaluate the safety and tolerability (Incidence of SAEs) of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. · 80 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Skin Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 11 open · Antimitotic agents 1 open · Tyrosine kinase inhibitors (TKIs) 17 · Alkylating agents 9 · Antimetabolites 7

Coming up

57studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 105 Skin Neoplasms studies recruiting now, 85 (81%) set no upper age limit and 9 (9%) stop at 75 or younger. 15 (14%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 25 (24%) take healthy volunteers.

Recruiting studies that take each age, of 105
AgeWomenMen
1010 (10%)9 (9%)
1899 (94%)98 (93%)
30100 (95%)99 (94%)
40100 (95%)99 (94%)
5099 (94%)99 (94%)
6599 (94%)99 (94%)
7596 (91%)96 (91%)
8595 (90%)95 (90%)

Across all 606 studies, recruiting or not: 10% stop at 75 or younger and 6% at 65; 15% take children; 2% are for women only and 1% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Skin Neoplasms studies take

Of 36 phase 1 interventional studies under Skin Neoplasms, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 149 mo28–57 · 36 studies——
Phase 260 mo35–97 · 36 studies——
Interventional, no phase27 mo10–66 · 116 studies—23 mo9–49 · 94 studies
Observational72 mo21–248 · 78 studies—139 mo24–… · 53 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 606. Browse all 606 → or search them.